- Home
- SNTI vs MRSN Comparison
SNTI vs MRSN Comparison
Compare SNTI & MRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNTI
- MRSN
- Stock Information
- Founded
- SNTI 2016
- MRSN 2001
- Country
- SNTI United States
- MRSN United States
- Employees
- SNTI N/A
- MRSN N/A
- Industry
- SNTI Biotechnology: Pharmaceutical Preparations
- MRSN Biotechnology: Pharmaceutical Preparations
- Sector
- SNTI Health Care
- MRSN Health Care
- Exchange
- SNTI Nasdaq
- MRSN Nasdaq
- Market Cap
- SNTI 39.6M
- MRSN 37.0M
- IPO Year
- SNTI N/A
- MRSN 2017
- Fundamental
- Price
- SNTI $1.39
- MRSN $7.35
- Analyst Decision
- SNTI Strong Buy
- MRSN Strong Buy
- Analyst Count
- SNTI 2
- MRSN 3
- Target Price
- SNTI $8.50
- MRSN $33.00
- AVG Volume (30 Days)
- SNTI 121.1K
- MRSN 63.1K
- Earning Date
- SNTI 11-13-2025
- MRSN 11-12-2025
- Dividend Yield
- SNTI N/A
- MRSN N/A
- EPS Growth
- SNTI N/A
- MRSN N/A
- EPS
- SNTI N/A
- MRSN N/A
- Revenue
- SNTI N/A
- MRSN $34,769,000.00
- Revenue This Year
- SNTI N/A
- MRSN N/A
- Revenue Next Year
- SNTI $150.00
- MRSN N/A
- P/E Ratio
- SNTI N/A
- MRSN N/A
- Revenue Growth
- SNTI N/A
- MRSN 16.14
- 52 Week Low
- SNTI $1.26
- MRSN $5.21
- 52 Week High
- SNTI $16.94
- MRSN $70.75
- Technical
- Relative Strength Index (RSI)
- SNTI 39.50
- MRSN 50.69
- Support Level
- SNTI $1.33
- MRSN $7.05
- Resistance Level
- SNTI $1.42
- MRSN $7.49
- Average True Range (ATR)
- SNTI 0.07
- MRSN 0.43
- MACD
- SNTI 0.02
- MRSN 0.01
- Stochastic Oscillator
- SNTI 44.83
- MRSN 58.95
About SNTI Senti Biosciences Inc.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.
About MRSN Mersana Therapeutics Inc.
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) that offer a clinically meaningful benefit for cancer patients with unmet needs. The Company's next-generation ADC platforms include Dolasynthen, which delivers a proprietary auristatin payload, and Immunosynthen, which delivers a proprietary stimulator of interferon genes (STING) agonist payload. Its pipeline includes Emi-Le (XMT-1660), XMT-2056, XMT-2068, and XMT-2175.